Corrigendum: Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction

Corrigendum: Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction

Bibliographic Details
Main Authors:	Michelle L. Pleet, Allison Mathiesen, Catherine DeMarino, Yao A. Akpamagbo, Robert A. Barclay, Angela Schwab, Sergey Iordanskiy, Gavin C. Sampey, Benjamin Lepene, Philipp A. Ilinykh, Alexander Bukreyev, Sergei Nekhai, M. Javad Aman, Fatah Kashanchi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-04-01
Series:	Frontiers in Microbiology
Subjects:	Ebola virus EBOV VP40 VLP exosomes ESCRT
Online Access:	http://journal.frontiersin.org/article/10.3389/fmicb.2018.00692/full

Similar Items

Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion
by: Michelle L. Pleet, et al.
Published: (2019-05-01)

Ebola virus-induced eye sequelae: a murine model for evaluating glycoprotein-targeting therapeuticsResearch in context
by: Ha-Na Lee, et al.
Published: (2024-06-01)

<i>Bacillus paranthracis</i> Isolate from Blood of Fatal Ebola Virus Disease Case
by: M. Jeremiah Matson, et al.
Published: (2020-06-01)

Human Parainfluenza Virus 3 Phosphoprotein Is a Tetramer and Shares Structural and Interaction Features with Ebola Phosphoprotein VP35
by: Joaquin Rodriguez Galvan, et al.
Published: (2021-10-01)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
by: Amanda N. Pinski, et al.
Published: (2020-09-01)

Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24
by: Palaniappan Ramanathan, et al.
Published: (2023-04-01)

Delayed recognition of Ebola virus disease is associated with longer and larger outbreaks
by: M. Jeremiah Matson, et al.
Published: (2020-01-01)

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease
by: Dylan M. Johnson, et al.
Published: (2024-07-01)

Virus-like particles based on rotavarus A recombinant VP2/VP6 proteins for assessment the antibody immune response by ELISA
by: Ilya E. Filatov, et al.
Published: (2023-05-01)

A Small-Particle Aerosol Model of Ebolavirus Zaire Infection in Ferrets
by: Courtney A. Cohen, et al.
Published: (2024-11-01)

Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds
by: Louis K. S. Darko, et al.
Published: (2021-11-01)

Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals
by: Gavin C. Sampey, et al.
Published: (2020-09-01)

Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products
by: Muhammad Hayat, et al.
Published: (2024-06-01)

On-Demand Patient-Specific Phenotype-to-Genotype Ebola Virus Characterization
by: Brett F. Beitzel, et al.
Published: (2021-10-01)

Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus
by: Zhe Zhang, et al.
Published: (2022-08-01)

Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs
by: Wei Ye, et al.
Published: (2023-03-01)

Evaluation of fendiline treatment in VP40 system with nucleation-elongation process: a computational model of Ebola virus matrix protein assembly
by: Xiao Liu, et al.
Published: (2024-04-01)

The Minor Matrix Protein VP24 from Ebola Virus Lacks Direct Lipid-Binding Properties
by: Yuan Su, et al.
Published: (2020-08-01)

Closer than ever to an Ebola virus vaccine
by: Logan Banadyga, et al.
Published: (2017-05-01)

Algal Lectin Griffithsin Inhibits Ebola Virus Infection
by: Leah Liu Wang, et al.
Published: (2025-02-01)

Ubiquitin Ligase SMURF2 Interacts with Filovirus VP40 and Promotes Egress of VP40 VLPs
by: Ariel Shepley-McTaggart, et al.
Published: (2021-02-01)

Computational Drug Design against Ebola Virus Targeting Viral Matrix Protein VP30
by: Arthi Venkatesan, et al.
Published: (2019-11-01)

Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in <i>Nicotiana benthamiana</i>
by: Maria Malm, et al.
Published: (2019-05-01)

Functional Importance of Hydrophobic Patches on the Ebola Virus VP35 IFN-Inhibitory Domain
by: Nodoka Kasajima, et al.
Published: (2021-11-01)

Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies
by: Supriya Ravichandran, et al.
Published: (2022-08-01)

Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination
by: Eve Richardson, et al.
Published: (2024-07-01)

Ebola virus sequesters IRF3 in viral inclusion bodies to evade host antiviral immunity
by: Lin Zhu, et al.
Published: (2024-01-01)

Frontal VP & VA Shunts Versus post parietal VP &VA Shunts
by: A- Hadi Khalili, et al.
Published: (2005-04-01)

Development of Monoclonal Antibody to Specifically Recognize VP0 but Not VP4 and VP2 of Foot-and-Mouth Disease Virus
by: Sun Young Park, et al.
Published: (2022-12-01)

To be or not to be phosphorylated: understanding the role of Ebola virus nucleoprotein in the dynamic interplay with the transcriptional activator VP30 and the host phosphatase PP2A-B56
by: Lennart Kämper, et al.
Published: (2025-12-01)

Molecular docking study of anti-viral FDA-approved drugs as novel entry and replication Ebola viral inhibitors
by: Saghi Sepehri, et al.
Published: (2019-04-01)

Adapting Simon’s Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates
by: Nancy A. Niemuth, et al.
Published: (2022-07-01)

In memory of V.P. Harchenko
Published: (2020-04-01)

Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats
by: Anitha D. Jayaprakash, et al.
Published: (2023-01-01)

Comparative analysis of the RVA VP7 and VP4 antigenic epitopes circulating in Iran and the Rotarix and RotaTeq vaccines
by: Tina Fallah, et al.
Published: (2024-07-01)

Biosynthesis of a VLP-type nanocarrier specific to cancer cells using the BEVS expression system for targeted drug delivery
by: Mohammad Sadegh Hashemzadeh, et al.
Published: (2023-02-01)

Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription
by: Jingliang Chen, et al.
Published: (2019-01-01)

Stability and integrity of self-assembled bovine parvovirus virus‑like particles (BPV‑VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment
by: Ashenafi Kiros Wubshet, et al.
Published: (2024-04-01)

Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection
by: Wakako Furuyama, et al.
Published: (2020-10-01)

Construction and efficacy of recombinant Newcastle disease virus co-expressing VP2 and VP3 proteins of very virulent infectious bursal disease virus
by: Tongfei Liu, et al.
Published: (2025-01-01)